← Leaderboards
Monique B Nilsson
University Of Tx Md Anderson Can Ctr
$584,885
Attributed
$584,885
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $140.3K · FY2021–25$200K$150K$100K$50K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$584,885 · 1
By mechanism
R50$584,885 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- John V. Heymach$11,138,593
- Scott Kopetz$13,199,822
- Cassian Yee$17,221,393
- Michael Wang$3,493,311
- Kapil N. Bhalla$16,921,043
Others in their field
Other Emerging Leaders on “Lung Neoplasms”
- Leonard Freedman · Leidos Biomedical Research, Inc.$50,919,602
- Greg Yothers · University Of Chicago$35,003,821
- Lynn Briscoe · Leidos Biomedical Research, Inc.$26,085,158
- Jeremy James Martinson · University Of Pittsburgh At Pittsburgh$15,658,268
- Rachana Agarwal · Leidos Biomedical Research, Inc.$15,241,462
- John Freymann · Leidos Biomedical Research, Inc.$14,011,208
Research focus
Lung NeoplasmsClinicAurora KinaseCollectionCritical PathwaysDependenceDisease ResistanceCellsDrug TargetingDrug ToleranceEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorFoxm1 GeneGeneticGrowthHormonesDrug ResistanceClinical TrialsInstitutionInterleukin-6LaboratoriesLaboratory ResearchLungMalignant Neoplasm Of Lung
Grant awards (5)
Targeting EGFR mutant tyrosine kinase inhibitors (TKIs) resistant and drug-tolerant persister cells in non-small cell lung cancer (NSCLC)$101,401
R50 · FY2025 · CA · contact PI
Targeting EGFR mutant tyrosine kinase inhibitors (TKIs) resistant and drug-tolerant persister cells in non-small cell lung cancer (NSCLC)$101,401
R50 · FY2024 · CA · contact PI
Targeting EGFR mutant tyrosine kinase inhibitors (TKIs) resistant and drug-tolerant persister cells in non-small cell lung cancer (NSCLC)$101,401
R50 · FY2023 · CA · contact PI
Targeting EGFR mutant tyrosine kinase inhibitors (TKIs) resistant and drug-tolerant persister cells in non-small cell lung cancer (NSCLC)$140,341
R50 · FY2022 · CA · contact PI
Targeting EGFR mutant tyrosine kinase inhibitors (TKIs) resistant and drug-tolerant persister cells in non-small cell lung cancer (NSCLC)$140,341
R50 · FY2021 · CA · contact PI